{
    "2019-04-12": [
        [
            {
                "time": "2019-04-12",
                "original_text": "J&J wins U.S. FDA approval for bladder cancer drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "approval",
                        "bladder cancer",
                        "drug"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Cramer's Game Plan: Remember this market 'has no memory' this earnings season",
                "features": {
                    "keywords": [
                        "Cramer",
                        "market",
                        "earnings season",
                        "memory"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Earnings Optimism Following Bank Results",
                "features": {
                    "keywords": [
                        "earnings optimism",
                        "bank results"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "banks"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Forward Guidance Will Make or Break JNJ Earnings",
                "features": {
                    "keywords": [
                        "forward guidance",
                        "JNJ",
                        "earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "U.S. FDA approves J&J's bladder cancer drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "approval",
                        "bladder cancer",
                        "drug"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "3 Earnings Reports to Watch Next Week",
                "features": {
                    "keywords": [
                        "earnings reports",
                        "next week"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal",
                "features": {
                    "keywords": [
                        "AZN",
                        "MRK",
                        "GSK",
                        "regulatory approvals",
                        "Sandoz",
                        "deal"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "XLV, FLN: Big ETF Outflows",
                "features": {
                    "keywords": [
                        "XLV",
                        "FLN",
                        "ETF outflows"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "ETFs"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "iShares Core S&P 500 ETF Experiences Big Inflow",
                "features": {
                    "keywords": [
                        "iShares",
                        "S&P 500",
                        "ETF inflow"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market",
                        "ETFs"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Looking for a Growth Stock? 3 Reasons Why Johnson & Johnson (JNJ) is a Solid Choice",
                "features": {
                    "keywords": [
                        "growth stock",
                        "JNJ",
                        "solid choice"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Health Care Sector Update for 04/12/2019: TCON, XFOR, CGC, JNJ, PFE, ABT, MRK, AMGN",
                "features": {
                    "keywords": [
                        "health care sector",
                        "update",
                        "TCON",
                        "XFOR",
                        "CGC",
                        "JNJ",
                        "PFE",
                        "ABT",
                        "MRK",
                        "AMGN"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Johnson & Johnson Is a Great Company Trading at a Fair Price",
                "features": {
                    "keywords": [
                        "JNJ",
                        "great company",
                        "fair price"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Rizmoic",
                        "Sandoz",
                        "Alcon"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}